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A B S T R A C T
Conjugation of small molecule agonists of Toll-like receptor 7 (TLR7) to proteins, lipids, or polymers is known to
modulate potency, and the physical form or formulation of these conjugates is likely to have a major eﬀect on
their immunostimulatory activity. Here, we studied the eﬀect of formulation on potency of a
1,2‑di‑(9Z‑octadecenoyl)‑sn‑glycero‑3‑phosphoethanolamine (DOPE) conjugated TLR7 agonist (DOPE-TLR7a)
alongside assessing physical form using Dynamic Light Scattering (DLS), Nanosight Particle Tracking (NTA)
analysis and Small Angle X-ray Scattering (SAXS). A very high potency of DOPE-TLR7a conjugate (EC50 around
9 nM) was observed either when prepared by direct dilution from DMSO or when formulated into 400–700 nm
large multilamella liposomes containing dimethyldioctadecylammonium bromide salt (DDA) and DOPE. When
prepared by dissolution in DMSO followed by dilution in aqueous culture medium, 93 ± 5 nm nanoparticles
were formed. Without dilution from solution in DMSO, no nanoparticles were observed and no im-
munostimulatory activity could be detected without this formulation step. SAXS analysis of the conjugate after
DMSO dissolution/water dilution revealed a lamellar order with a layer spacing of 68.7 Å, which correlates with
arrangement in groups of 3 bilayers. The addition of another immunostimulatory glycolipid, trehalose‑6,6‑di-
behenate (TDB), to DOPE:DDA liposomes gave no further increase in immunostimulatory activity beyond that
provided by incorporating DOPE-TLR7a. Given the importance of nanoparticle or liposomal formulation for
activity, we conclude that the major mechanism for increased potency when TLR7 agonists are conjugated to
macromolecules is through alteration of physical form.
1. Introduction
Recently the molecular pathways of immune activation both by
pathogen associated molecular patterns (PAMP) recognition via pattern
recognition receptors (PRR) such as TLR (Medzhitov and Janeway,
1998; Medzhitov et al., 1997; Takeda and Akira, 2004) and also by
particulate adjuvants for example by nucleotide-binding domain, leu-
cine-rich-containing family, pyrin domain-containing-3 (NLRP3)/in-
ﬂammasome mediated pathways (Eisenbarth et al., 2008) have been
elucidated. These advances include insight into the immunomodulatory
properties of alum, which was thought to rely on a deposition eﬀect to
enhance the persistence of presented antigens to antigen presenting
cells (APC) (Verdier et al., 2005). However this paradigm has been
challenged by studying the rapid release of 14C labelled antigens
administered with alum (Gupta et al., 1996) and the excision of the
injection site shortly after administration does not signiﬁcantly impact
on the immune response to the antigen (Lindblad, 2004). The increased
immunogenicity of alum adsorbed antigen may therefore lie in the ef-
ﬁciency of APC to phagocytise particulate antigens compared to the
macropinocytosis of antigen alone despite the lack of PRR agonist
(Moreﬁeld et al., 2005). The physical form of the antigen is therefore
clearly of equal importance to associated immunostimulatory activity
through PRR. Recent attempts at rational vaccine design therefore
manipulate both the innate molecular recognition pathways and the
physical form of the antigen. For example, when a small molecule
TLR7/8 agonist was conjugated to a temperature responsive polymer
support to form nanoparticles, the most signiﬁcant increase in im-
munogenicity was seen from the formation of particles as opposed to
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modulation of TLR7/8 agonist loading (Lynn et al., 2015).
This detailed molecular and cellular insight conﬁrms multiple pre-
vious observations highlighting the importance of formulation and
physicochemical form of vaccine adjuvants for maximising im-
munostimulatory activity. For example, an increase in potency fol-
lowing liposomal formulation on muramyl dipeptide was observed as
far back as 1984 (Sone et al., 1984) the immunostimulatory activity of
which has been more recently attributed to nucleotide-binding oligo-
merization domain-like receptors (NOD) activation. Likewise, the in
vivo adjuvant activity of TLR2 stimulatory lipopeptides was found to be
strongly dependent on physical form, with particulate components
primarily responsible for vaccine activity in vivo (Tsunoda et al., 1999).
The physical form and self-assembly properties of TLR2 stimulatory
lipopeptides have recently been studied in much greater detail, re-
vealing that aggregation into micellular or ﬁbrillar structures, has a
profound eﬀect on biological activity (Castelletto et al., 2016; Hamley
et al., 2014).
The most intensely studied synthetic immunostimulatory small
molecule PRR agonists target the sensors of viral RNA TLR7 and TLR8
(Heil et al., 2003; Hemmi et al., 2002; Takeda and Akira, 2004). Indeed,
the imidazoquinoline Imiquimod was clinically approved in 1997,
5 years before its ability to trigger TLR7 was identiﬁed (Hemmi et al.,
2002). Many studies have reported the relative potency of diﬀerent
families of small molecule agonists for TLR7 and TLR8, and while dif-
ferent cellular assays and endpoints are used, it is still informative to
compare their potency which varies widely. To date, the most potent
reported were in a library of 2‑substituted 8‑hydroxyadenines some of
which had minimum eﬀective concentrations (MEC) as low as 1–10 nM
(Hirota et al., 2002). The majority of compounds in contrast have re-
ported activity in the 0.1–10 μM range including imidazoquinolines
with a ED50 or MEC in μM level (Kurimoto et al., 2004). Several
structure-activity relationship (SAR) studies have focused on identi-
fying a suitable location for conjugation to protein antigens or macro-
molecules without reducing potency following conjugation (Chan et al.,
2009; Wille-Reece et al., 2005a; Wu et al., 2007a). Interestingly, one of
the most studied examples, UC-1V150, is by no means the most potent
TLR7 molecule in its unconjugated form, with EC50 of around 500 nM
(Wu et al., 2007a). This contrasts with structurally similar 8‑ox-
oadenine derivatives reported with EC50 as low as 5 nM (Czarniecki,
2008) and rationally designed compounds based on pharmacophore
molecular docking studies as low as 0.5 nM have been reported (Yu
et al., 2013).
The potency of UC-1V150 is signiﬁcantly increased following con-
jugation to proteins such as serum albumin (Wu et al., 2007b) even
taking into account that the conjugates typically have a drug substitu-
tion ratio of up to 5:1 meaning that stated molar concentrations un-
derestimate the total quantity of TLR7-agonist small molecule drug by
up to 5-fold. Similarly conjugation of UC1V150 to the anti-CD20 anti-
body rituximab demonstrates a similar increase in potency compared to
the free unconjugated TLR7 agonist (Gadd et al., 2015). Imidazoqui-
noline compounds such as 3M-012 conjugated to HIV Gag P41 protein
show a similar increase in potency over the unconjugated and the
protein mixed with TLR7/8 agonist (Wille-Reece et al., 2005b). As well
as protein/peptide conjugation of TLR agonists, other published ex-
amples of macromolecular conjugates include polymers such as PEG
(Chan et al., 2011), phospholipids (Chan et al., 2009) and glyco-
conjugates (Donadei et al., 2016; Shinchi et al., 2015). These examples
typically note an increase in potency compared to the unconjugated
agonist or agonist mixed with the antigen/scaﬀold. Other TLR agonists
have likewise been conjugated to macromolecules with modulation of
activity (Yu et al., 2017). Furthermore, conjugation alters in vivo re-
sponses including altered duration and location of cytokine induction,
and when humoral response was studied modiﬁcation of the antibody
titre and ratio of immunoglobulin G (IgG) subtypes (Donadei et al.,
2016; Shinchi et al., 2015; Smirnov et al., 2011). Further beneﬁts of
conjugation were also observed beyond simply increasing potency; for
example conjugated or unconjugated TLR7 agonist were both able to
induce dendritic cell (DC) maturation, but cross presentation was in-
creased when TLR7 agonist was conjugated directly to antigen (Oh
et al., 2011; Oh and Kedl, 2010).
A lipid modiﬁed member of the imidazoquinoline family TLR7
agonist was shown to be a potent vaccine adjuvant in vivo, but the in
vitro immunostimulatory activity of this compound was not reported
(Smirnov et al., 2011). However, the in vitro activity of the un-
conjugated agonist was reported in the low μM range similar for the
structurally related R848 compound. In contrast to the highly potent
UC-1V150 conjugated to the phospholipid DOPE that had EC50 of ap-
proximately 50 nM in vitro when analysing IL12p40 concentrations,
compared to the unconjugated agonist of aproximatly 1 μM (Chan et al.,
2009). Separately, immunostimulatory liposomal formulations have
been studied extensively for vaccine formulation as an antigen delivery
and/or depot system. While the majority of liposome-forming lipids
lack intrinsic immunostimulatory activity, addition of the glycolipid
trehalose‑6,6‑dibehenate (TDB) provides direct immunostimulatory
activity to liposomes by triggering the PRR minkle via Syk/CARD9
(Matsunaga and Moody, 2009; Vangala et al., 2006; Yamasaki et al.,
2008).
Here, we studied the inﬂuence of the physical form of lipid con-
jugated TLR7 agonist on immunostimulatory potency. We speciﬁcally
focussed on phospholipid-conjugated forms of 2-substituted 8‑hydro-
xyadenines which are potent TLR7 agonists (Chan et al., 2009). The
physical form of this conjugate and its inﬂuence on biological activity
has not previously been reported, and we therefore describe here how
either nanoparticles formed by dilution from solvent, or a liposomal
formulation, are required for this conjugate to be active in vitro and
provide further physical characterisation by SAXS.
2. Material and methods
2.1. Materials
RPMI 1640 supplemented with Glutamax & HEPES & Phenol Red,
performance plus heat inactivated foetal bovine serum, phosphate
buﬀered saline and 2‑mercaptoethanol were from Life Technologies
(Paisley, UK). ExtrAvidin alkaline phosphatase conjugate, Sigmafast
pNPP, PBS tablets, sodium azide and EDTA (0.5M) were from Sigma
Aldrich (Gillingham, UK). The IL-12p40 capture antibody C 15.6 and
biotinylated IL-12p40/70 detection antibody C17.8 were from
eBioscience (Hatﬁeld, UK). Nunc® Maxisorb 96 well ELISA plates were
from Thermo Fisher scientiﬁc (Paisley, UK). Reagents for chemical
synthesis were purchased from Sigma Aldrich (Gliiingham, UK) or
Fluorochem (Hadﬁeld, UK) and used without further puriﬁcation.
2.2. Synthesis
TLR7 agonist with carboxyl site on the para-benzyl group for con-
jugation (7, Fig. 1) and DOPE-TLR7 agonist conjugate (8, Fig. 1) were
synthesised according to previous methods (Wu et al., 2007b) and ob-
tained in good yields as white crystalline powders. A similar TLR7
agonist without the carboxyl conjugation site on the para-benzyl group
(9, Fig. 1) was also synthesised for activity comparison. Full synthetic
methodology and comprehensive characterisation data is provided in
Supplementary information, including a crystal structure for 9 (Sup-
plementary information).
4‑{[6‑Amino‑2‑(2‑methoxyethoxy)‑8‑oxo‑7H‑purin‑9(8H)‑yl]me-
thyl}benzoic Acid (7, Fig. 1)
1H NMR (DMSO‑d6) δ 12.94 (1H, s, ArC(O)OH), 10.03 (1H, s,
NHC(O)N), 7.89 (2H, d J=8.2, 2x o-ArH), 7.39 (2H, d, J=8.2, 2x m-
ArH), 6.51 (2H, s, NH2), 4.94 (2H, s, ArCH2N), 4.25 (2H, t, J=4.2,
OCH2CH2OCH3), 3.57 (2H, t, J=4.2, OCH2CH2OCH3), 3.26 (3H, s,
OCH2CH2OCH3). 13C NMR (DMSO‑d6) δ167.00, 159.83, 152.17,
149.08, 147.75, 141.98, 129.83, 129.55, 127.39, 98.34, 70.15, 65.26,
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58.01, 42.12. HRMS calculated for C16H18O5N5+ (MH+) 360.1302
found 360.1302.
IR (ν, cm−1): 3351, 3165, 2956 (Broad), 1703, 1630, 1603
(2R)‑3‑(((2‑(4‑((6‑amino‑2‑(2‑methoxyethoxy)‑8‑oxo‑7,8‑dihydro‑9H‑
purin‑9‑yl)methyl)benzamido)ethoxy)(hydroxy)phosphoryl)oxy)propa-
ne‑1,2‑diyl dioleate (8)
1H NMR (DMSO‑d6, 700MHz, 45 °C): δ 10.35 (1H, s, NHC(O)N),
9.97 (1H, bs, ArC(O)NHCH2CH2), 9.37 (1H, bs, PO3OH), 7.86 (2H, d, J
8.2, 2x o-ArH), 7.34 (2H, d, J 8.2, 2x m-ArH), 6.60 (2H, bs, NH2), 5.31
(4H, m, 2x CH2CHCHCH2), 5.09 (1H, m, POCH2CHCH2O), 4.89 (2H, s,
NCH2Ar), 4.29 (1H, dd, J 3.1, 12.0, C(O)NHCH2CH2OPO3) 4.25 (2H, m,
OCH2CH2OCH3), 4.09 (1H, m, C(O)NHCH2CH2OPO3), 3.84 (2H, bs,
POCH2CHCH2O), 3.81 (2H, bs, POCH2CHCH2O) 3.57 (2H, m,
OCH2CH2OCH3), 3.26 (3H, s, OCH2CH2OCH3), 3.17, (1H, d, J 5.1), 2.24
(4H, m, 2x OC(O)CH2CH2), 1.95 (8H, m, 2x CH2CH2CHCHCH2CH2),
1.48 (4H, m, 2x OC(O)CH2CH2), 1.23 (40H, m, Lipid tail CH2), 0.85
(6H, m, 2x CH2CH2CH3).
13C NMR (DMSO‑d6, 175MHz) δ 173.13, 172.88, 160.43, 152.74,
149.62, 148.45, 140.74, 134.04, 130.22, 128.01, 127.9, 99.00, 70.82,
62.93, 58.66, 46.04, 42.69, 40.59, 34.15, 33.97, 31.88, 29.70, 29.69,
29.44, 29.30, 29.23, 29.19, 29.12, 29.10, 29.03, 28.99, 19.16, 14.53.
HRMS calculated for C57H94N6O12P+ (MH+) 1085.6662 found
1085.6677
IR (ν, cm−1): 3438, 3352, 3193, 2927, 2856, 1742, 1708, 1674,
1638, 1617.
2.3. Endotoxin testing
Endotoxin is a component of bacterial cell walls with potent in-
ﬂammatory response through TLR4 and is also a common laboratory
contaminant. Synthesis and conjugation was completed in sterile
environment and only endotoxin free reagents used. To conﬁrm the
absence of endotoxin contamination, a LAL assay was used to quantify
the amount of soluble endotoxin in all reagents. Endotoxin content of
sample was analysed by a Hycult biotech (Uden, Netherlands): LAL
Chromogenic Endpoint Assay Endotoxin quantiﬁcation kit and was
performed according to manufacturer's instruction, unless otherwise
stated all compounds tested were below the limit of detection of
0.08 EU/mL.
2.4. Formulation of nanoparticles and liposomes
2.4.1. Nanoparticle formulation of DOPE-TLR7a agonist conjugate
Weighed amounts of DOPE-TLR7 agonist conjugates (typically 1mg,
0.9 μmol) were pre-solubilized with DMSO (50 μL) before diluting with
H2O to form a stock solution at 150 μM. Samples were then diluted in
ether H2O or complete cell culture media (RPMI 1640, 10% FBS, 50 μM
2-ME) from the stock solution. Solutions of DOPE-TLR7 agonist con-
jugates were tested at concentrations relevant for in vitro stimulation of
RAW 264.7 macrophages (1–1000 nM). Unconjugated TLR7a or DOPE-
TLR7a conjugates stored as either dry powder or in complete media as
nanoparticle formulations showed no diﬀerence in activity when stored
at −20 °C over a period of 6months. Although not formally evaluated,
we have no evidence to suggest any instability of these conjugates upon
storage.
2.4.2. Production of liposomes containing TDB and DOPE-TLR7 agonist
conjugates
Multilamellar vesicles (MLV) were synthesised by using the original
lipid-ﬁlm hydration method (Bangham et al., 1965). MLV were selected
without further sonication or homogenization because previous studies
had shown that liposomal size had relatively little impact on im-
munostimulatory potency (Henriksen-Lacey et al., 2011). DDA, TDB
A
B
C
Fig. 1. Synthesis scheme of carboxyl modiﬁed TLR7 agonist (A). Synthesis of DOPE-TLR7a agonist conjugate by conjugation of carboxy modiﬁed TLR7 agonist to
phospholipid DOPE (B) and diagram of TLR7 agonist lacking a conjugation moiety (C).
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and DOPE-TLR7 agonist conjugate were dissolved in chloroform/me-
thanol (9:1 by volume) to give 10mg/mL stock solutions. DDA was
used as the core constituent of MLVs and used at 60 w/v% when TDB
was present or 80 w/v% when no TDB was incorporated. DOPE was
used at 20 w/v% and substituted accordingly with DOPE-TLR7 agonist.
The organic solvent was removed by rotary evaporation, followed by
ﬂushing with N2 to form a thin lipid ﬁlm on the bottom of a round-
bottomed ﬂask. The lipid ﬁlm was hydrated in 10mM Tris-buﬀer at
pH 7.4 by heating for 20min at 60 °C. The phase transition temperature
(Tm) of DDA is 47 °C. This general method to formulate MLVs was used
to produce a variety of liposomal formulations as listed in Table 1. MLV
formulations were stable for a period of up to 2 weeks when stored at
4 °C, at which point aggregation and was evident and a reduction in
activity was observed.
To clarify the ﬁnal concentrations of immuno-modulatory compo-
nents in each preparation and the calculations involved to determine
the concentration of compounds used in vitro are described in more
detail as follows. To produce MLVs with 20 w%/v% of TLR7a-DOPE
conjugate: 125 μL of DDA (10mg/mL) was transferred to a round
bottom ﬂask with the addition of 25 μL of DOPE-TLR7a conjugate
(10mg/mL). Following the above procedure, the lipid cake was then
resuspended in 1mL of Tris-buﬀer to give a ﬁnal following concentra-
tion of compounds: DDA=1.25mg/mL or 1.98mM, DOPE-
TLR7a=0.25mg/mL or 230 μM, TDB=0.25mg/mL or 250 μM. MLV
were then diluted into complete culture medium to the desired con-
centration for in vitro stimulation assays. When both TLR7a-DOPE
conjugate and TDB were present in MLVs, the concentration of DOPE-
TLR7a was used to determine dosing during in vitro stimulations assays.
2.5. Particle size analysis using Nanosight Tracking Analysis (NTA) and
Dynamic Light Scattering (DLS)
Samples were prepared in 1mL volume using milliQ ultrapure water
for NTA analysis, ﬁltered through a 0.45 μm syringe ﬁlter immediately
prior to use. NTA was performed on a LM10 system with LM14 top plate
and 533 nm laser (Malvern, UK). Flow rate was determined by software
and set to 30 AU. Videos were recorded 5 time for each sample, 60 s
each, samples were repeated 3 times at a controlled temperature of
25 °C. A 200 nm particle standard was used as a calibration run diluted
1:1000 in miliQ water. For samples analysed in complete media, de-
tection threshold was increased to 6 to reduce autoﬂuorescece noise. All
analysis was performed using NTA software v3.1 (Malvern, UK).
Liposomes were characterized using DLS measured used a Zetasizer
Nano-ZS (Malvern, UK). Samples were diluted into ultrapure water to
appropriate concentrations in low volume plastic cuvettes (Fisher
Scientiﬁc). A dispersant refractive index of 1.33 and material refractive
index of 1.45 was used for all samples. Individual measurements were
carried out for 10 s per run, with 12 runs per reading, repeated in tri-
plicate. This was repeated for three separate samples at 25 °C. ξ-
Potential values were also measured; using DTS-1061 folded capillary
tube cuvettes (Malvern, UK). Samples were diluted 1:100 in ultrapure
water to the same concentration used in sizing experiments. Samples
were measured using 20 sub-runs per reading, repeating 3 times for
each sample. Each sample was measured three times and the results
were processed using the Smoluchowski model (Fκa= 1.50).
2.6. SAXS characterisation of DOPE-TLR7a conjugates
2.6.1. Sample preparation for Small Angle X-ray Scattering (SAXS)
An aliquot of DOPE-TLR7a conjugate was ﬁrst dissolved in DMSO
then further diluted in TRIS buﬀered saline (TBS; 0.05M Tris, 0.15M
NaCl, pH 7.6) to give the corresponding concentrations used for SAXS
experiments. 1 wt% DOPE-TLR7a in 0.02 vol DMSO/vol TBS was di-
luted with TBS to give (for example) 0.25 wt% DOPE-TLR7a in 0.005
vol DMSO/vol TBS.
2.6.2. Small Angle X-ray Scattering (SAXS)
Synchrotron SAXS experiments on solutions were performed using a
BioSAXS robots at beamline BM29 (ESRF, France). Solutions were
loaded into the 96 well plate of an EMBL BioSAXS robot, and then in-
jected via an automated sample exchanger into a quartz capillary
(1.8 mm internal diameter) in the X-ray beam. The quartz capillary was
enclosed in a vacuum chamber, in order to avoid parasitic scattering.
After the sample was injected in the capillary and reached the X-ray
beam, the ﬂow was stopped during the SAXS data acquisition. BM29
operated with an X-ray wavelength λ=1.03 Å (12 keV). The images
were captured using a PILATUS 1M detector, while data processing was
performed using dedicated beamline software ISPYB (BM29).
2.7. In vitro immunostimulatory activity with RAW264.7 macrophage cell
line
Raw 264.7 macrophages were subcultured according to ATCC
methods: Complete media contained RPMI 1640 Glutamax® (10% FBS,
2‑Mercaptoetanol 0.05mM). Cells were cultured at 37 °C 5% CO2 in T-
75 ﬂasks until approximately 80% conﬂuency. Cells were then detached
using a solution of EDTA in PBS (1mM, 10mL) per T-75. Cell suspen-
sions were then centrifuged at 200×g for 5min. The supernatant was
removed then the pellet re-suspended in complete media (5mL). Cells
were then re-suspended in fresh culture media at 2× 105/mL.
Stimulation assays were performed in tissue culture grade 96 well
plates. Test compounds were diluted serially 1:2 (100 μL ﬁnal volume)
in complete media (RPMI 1640, 10% FBS, 0.05mM 2-ME) then
2×106 cells/mL freshly passaged cells were added in 100 μL to give a
ﬁnal volume of 200 μL. Plates were incubated for 24 h before the ana-
lysis of supernatants for pro-inﬂammatory cytokines. IL-12p40 con-
centrations in supernatants of RAW 264.7 stimulation assays were de-
termined by sandwich ELISA. Brieﬂy, Nunc Maxisorb 96 well ELISA
plates were coated overnight with IL-12p40 capture antibody (C15.6) at
2 μg/mL in carbonate buﬀer (pH 9.6, 50 μL per well), followed by 2 h
with 200 μL per well block buﬀer (PBS, 2.5 v/v% FBS, 0.02 w/v%
NaN3). 100 μL per well biotinylated detection antibody (C17.8) at 1 μg/
mL in block buﬀer was added. Stimulated RAW 264.7 supernatants
were diluted 1:7.5 in block buﬀer, and compared to 1:2 dilution of
recombinant IL-12p40 standards with a top concentration of 10 ng/mL
in block buﬀer, with 150 μL sample per well. ExtrAvidin alkaline
phosphatase conjugate was prepared 3:10,000 dilution in PBS.
3. Results
3.1. In vitro immunostimulatory activity of lipid conjugate nanoparticles
The TLR7 agonist UC-1V150 was conjugated to the phospholipid
DOPE as previously described and noted for their remarkable potency
compared to the unconjugated TLR7 agonist (Chan et al., 2009). We
discovered that pre-dissolving of the DOPE-TLR7a agonist conjugate in
DMSO was required to detect any activity with in vitro stimulation
(Table 2 and Fig. 2). We hypothesised that DOPE-TLR7a would be likely
to form micelles or nanoparticles in aqueous suspension following di-
lution from DMSO solution. To investigate the potency of alternative
formulations of the lipid-conjugated TLR7 agonist we added the con-
jugate to DOPE:DDA liposomes and found that this likewise increased
Table 1
Composition of MLVs containing DOPE-TLR7a conjugate, TDB and DOPE.
MLV composition TDB w%/v
% (μM)
DOPE-TLR7a agonist
w%/v% (μM)
DOPE w%/v%
(μM)
0% DOPE-TLR7a− TDB 0 (0) 0 (0) 20 (336)
0% DOPE-TLR7a+TDB 20 (250) 0 (0) 20 (336)
1% DOPE-TLR7a− TDB 0 (0) 1 (11.5) 19 (320)
20% DOPE-TLR7a− TDB 0 (0) 20 (230) 0 (0)
20% DOPE-TLR7a+TDB 20 (250) 20 (230) 0 (0)
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potency by>10-fold compared to unconjugated TLR7 agonist (Fig. 2B
and Tables 2 and 3).
Liposomes were analysed by DLS and found to have similar char-
acteristics to DDA:TDB MLVs. The incorporation of TLR7-agonist con-
jugated DOPE had little eﬀect on size distribution (Table 3). Like
DMSO-dissolved/diluted nanoparticles, liposomes containing TLR7
agonist showed potent in vitro immunostimulatory activity with an
EC50 of around 9 nM (Table 2, Fig. 2B). Interestingly, when we changed
the liposomal composition by reducing the TLR7 content, a signiﬁcant
reduction in activity was observed and found that there was no additive
or synergistic increase in activity when TLR7 agonist was combined
with the Minkle/Syk/CARD9 activating TDB. This was in line with
previous studies where TDB was shown not to synergise with TLR3 and
TLR9 agonists for vaccine potency in MLVs (Milicic et al., 2012).
3.2. High potency of lipid conjugated TLR7 agonist depends on nanoparticle
formation or liposomal formulation
The poor water solubility of the lipid conjugated TLR7 agonist
prevents direct addition of this compound to in vitro im-
munostimulatory assays, and it was therefore diluted in DMSO prior to
dilution into culture. We hypothesised that DOPE-TLR7a would be
likely to form micelles or nanoparticles in aqueous suspension following
dissolution in DMSO and dilution into water or culture medium. We
therefore used nanosight particle tracking analysis (NTA) to determine
the physical form of this preparation, and found nanoparticles with a
mean diameter of 93 ± 1 nm when diluted into ultrapure water.
Complete cell culture medium showed background particulate matter
as expected given the high protein content and heterogenous compo-
sition of heat inactivated foetal bovine serum. A background ﬂuores-
cence was also observed from phenol red in the culture medium, which
increased noise and reduced sensitivity with control 100 nm latex
particles. The increased viscosity of complete media over H2O was
taken into account by software correction viscosity values at 25 °C for
water= 0.89 cP and complete media= 0.96 cP. However, when di-
luted from DMSO into culture medium an increase in size of the DOPE-
TLR7 agonist conjugate was observed comparing to ultrapure water.
The increase from 93 ± 1 nm in water compared to 155 ± 5 nm in
culture medium could be attributed to agglomeration of particles, or to
incorporation of media components into micelles/nanoparticles. The
reduction of particle frequency in DOPE-TLR7a conjugates - not mir-
rored by the 100 nm latex standard - also supported the possibility of
agglomeration (Table 4).
3.3. Structure analysis
To determine the physical form of the lipid conjugate in micellar/
nanoparticulate form, 0.15, 0.4 and 1wt% DOPE-TLR7a was prepared
by dissolution/dilution and analysed by SAXS (Fig. 4). The SAXS scat-
tering shows two distinct peaks, at spacings d=2π /qo=68.7 and
33.9 Å (qo=position of the maxima in the scattering curve) and at a
positional ratio 1:2. These peaks suggest that DOPE-TLR7a is arranged
in a lamellar order with a layer spacing of 68.7 Å. The SAXS data for
1 wt% DOPE-TLR7a was modelled according to the form factor for a
bilayer structure, comprising three Gaussian functions to represent the
electron density variation across the two headgroups and the dense
lipid core (Pabst et al., 2000). The interaction between the bilayers was
Table 2
Immunomodulatory properties of TLR7 agonists, conjugates and liposomes.
Sample EC50 nM MEC nM
Conjugates Unconjugated TLR7 Agonist
(8)
483 ± 25 74
Unmodiﬁed TLR7 Agonist
(9)
620 ± 19 190
DOPE-TLR7a+DMSO 9 ± 1 <1
DOPE-TLR7a−DMSO No activity
(> 2000 nM)
No activity
(> 2000 nM)
Liposomes MLV 1% DOPE-TLR7a 45 ± 23 6
MLV 20% DOPE-TLR7a 34 ± 20 <2
MLV 20%
DOPE-TLR7a+TDB
33 ± 19 <2
MLV+TDB 223 ± 173 <24
MLV no immunostimulatory
agent
> 200,000 > 200,000
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Fig. 2. IL-12p40 concentration in supernantants of RAW 264.7 macrophages
cultures stimulated with Unconjugate TLR7 agonist, Unconjugated DOPE, TLR7
agonist mixed with DOPE 1:1 and DOPE-TLR7a conjugate (A). IL-12p40 con-
centration in supernatants of RAW 264.7 macrophages cultures after stimula-
tion with MLV containing DDA+TDB, DDA+DOPE, DDA+1% (w/v) DOPE-
TLR7a conjugate, DDA+20% (w/v) DOPE-TLR7a conjugate, DDA+TDB 20%
(w/v)+20% (w/v)DOPE-TLR7a conjugate and TLR7 agonist (B). n=3, error
bars show standard deviation.
Table 3
Z-Average, PDI and Zeta potentials of MLVs determined by DLS.
LIPOSOME composition Z-average size (nm) PDI Zeta potential (mV)
0% DOPE-TLR7a− TDB 636 0.45 59 ± 9
0% DOPE-TLR7a+TDB 679 0.18 76 ± 20
1% DOPE-TLR7a− TDB 424 0.80 67 ± 12
20% DOPE-TLR7a− TDB 526 0.34 65 ± 11
20% DOPE-TLR7a+TDB 616 0.37 60 ± 20
Table 4
Particle frequency of DOPE-TLR7a conjugate or 100 nm latex standards in
complete media or milliQ water determined by NTA.
Sample Complete media counts per mL H2O counts per mL
DOPE-TLR7a 3.6×108 8× 108
100 nm latex 1.15× 109 1.2× 109
Blank 1× 106 5× 105
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described by a modiﬁed Caillé structure factor (Caillé, 1972). The
model and its application to lipid-based bilayer structures have been
described in detail in our previous papers (Castelletto et al., 2013,
2012). The ﬁtting was implemented using the software SASﬁt (Breßler
et al., 2015). Fig. 4b shows the ﬁtting of the SAXS data for 1 wt% DOPE-
TLR7a using this model. The ﬁtted parameters are listed in Table 5, and
the organization of DOPE-TLR7a, according to data in Fig. 4 and the
parameters in Table 5 is illustrated in Fig. 5.
The ﬁtting of the SAXS data shows that DOPE-TLR7a molecules are
organized in bilayers with a repeat distance of 77 ± 25 Å, such that the
parameters listed in Table 5 are correlated in groups over ~3 bilayers.
The repeat distance provided by the SAXS ﬁtting is in good agreement
with the lamellar parameter 68.7 Å measured from the SAXS curve for
0.14–1wt% DOPE-TLR7a (Fig. 4a). In contrast, SAXS experiments
measuring the structure of pure DOPE lamellar provide a layer spacing
of 74.6 Å in water (Koltover, 1998).
4. Discussion
Conjugation of TLR7a to the phospholipid DOPE has previously
been shown to promote strong pro-inﬂammatory response in vitro, with
a similar increase in potency to other TLR7/8 agonist conjugates to
macromolecules such as polymers and peptides. However the inad-
vertent self-assembly of this compound by dissolving in DMSO prior to
Table 5
SAXS parameters extracted from the ﬁttings of the experimental data shown in Fig. 4b.
2zH [Å] Δ2zH [Å] ρH [rel. units] σH [Å] ρC [rel. units] σC [Å] N do [Å] η Ndiﬀ
66 25.9 9.3e−4 5.7 1.2e−4 5.7 3.2 67 2.2 3.5
Key: Gaussian bilayer form factor: Gaussian half-width at half-maximum for polydispersity Δ2zH, inter-head group thicknesses 2zH, Gaussian half-width for outer layer
surface σH, electron density for headgroup ρH, Gaussian half-width for inner layer σC, relative electron density for inner layer ρC. Caillé structure factor: diﬀuse
background Ndiﬀ; total number of layers N; layer thickness do; Caillé parameter η.
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addition to culture, to overcome the poor aqueous solubility has not
previously been investigated. Likewise, the potency of liposomes in-
corporating DOPE-TLR7a conjugates has not been reported. We show
that attempts to directly disperse DOPE-TLR7a directly into aqueous
solution shows no sign of particulates when analysed by light scattering
techniques (Fig. 3B) and likewise no in vitro pro-inﬂammatory activity
can be detected without dilution from DMSO solution or incorporation
into liposomes (Table 2 and Fig. 3A). Separately dissolving the TLR7a
agonist plus DOPE in DMSO before mixing and diluting in aqueous
media showed no increase in the in vitro pro-inﬂammatory response,
demonstrating incorporation via covalent coupling to lipid group is
essential to inﬂuence potency (Fig. 2A). Similar activity was observed
between TLR7 agonists without conjugation to the lipid group either
with a functional group for conjugation, such as a carboxylic acid (7),
and without functional group at the para-benzyl position (9), sug-
gesting the alteration of activity is due to lipid conjugation not simply
variation in groups on this para-benzyl position (Table 2). We were able
to diﬀract a crystal of compound 9 to conﬁrm for the ﬁrst time the solid
state structure of this important immunostimulatory compound (Sup-
plementary information).
Either using DMSO to dissolve the DOPE-TLR7a conjugate prior to
dispersion by dilution in aqueous solvents, or using well-established
lipid cake hydration method of forming MLVs showed a clear and large
increase in the number of particles formed and also a strong pro-in-
ﬂammatory response in vitro (Fig. 3). Complete culture media typically
contains 10% FCS in addition to a large amount of amino acids, mi-
nerals and carbohydrates. Changes in ionic strength, counterions, pro-
tein concentration and pH can inﬂuence the formation, stability and
aggregation of particles (Maeda et al., 1997; Palladino and Ragone,
2011). Changing the solvent from water to complete media inﬂuenced
the average particle size and frequency of DOPE-TLR7a particles de-
tected by light scattering (Fig. 3c and Table 4). The increase in particle
size and reduction in particle frequency could be explained by the ag-
glomeration of DOPE-TLR7a particles. Control 100 nm latex particles
analysed in complete media displayed a broadening of particle size, the
mean increasing from 100 nm to 120 nm but particle frequency re-
mained constant (Table 4), suggesting that complete media may in-
teract directly with DOPE-TLR7a aﬀecting particle size and frequency.
TDB is not only an immunostimulatory glycolipid, but has also been
reported to have a stabilising eﬀect on cationic MLVs constructed from
DDA and DOPE (Christensen et al., 2007). Using DLS to analyse MLV
size distribution (Table 3) indicated that the inclusion of TDB did re-
duce the PDI of MLV formed from DDA, DOPE plus DOPE-TLR7a. The
resulting MLV all showed a strong pro-inﬂammatory induction in vitro.
Previous reports suggested that the immunostimulatory activity of TDB
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does not synergise with TLR 3 and 9 agonists,(Milicic et al., 2012) and
we similarly found no evidence of synergistic eﬀect of combining
DOPE-TLR7a and TDB within liposomes in this simple in vitro system.
Adding TDB to MLV containing 20% DOPE-TLR7a showed no increased
pro-inﬂammatory activity (Fig. 3). Further study is now required to
evaluate the impact on formulation on diﬀerent cell types expressing
TLR7, and molecular methods such as evaluation in knockout cells, or
reporter cell lines exclusively expressing a panel of TLRs and other PRR,
is now justiﬁed to understand if conjugation also aﬀects receptor spe-
ciﬁcity, as well as potency, of these compounds. Initial experiments
using a GFP inducible Nf-κB cell line lacking TLR7 known as GTPT3
(Bloor et al., 2008) showed no induced GFP expression over back-
ground when stimulated with unconjugated TLR7 agonist, DOPE-TLR7a
conjugate or liposomes containing DOPE-TLR7a conjugate, but did
show a dose dependant response to LPS (data not shown). This pre-
liminary test suggests that DOPE-TLR7a conjugate in micellar or lipo-
somal formulation remains speciﬁc for TLR7.
5. Conclusions
This study links the physical form of DOPE-TLR7a conjugates in
aqueous dispersion to their biological activity in vitro, which has not
been reported previously. Our data shows that the formation of TLR7
agonist containing nanoparticles distinctly modulates pro-inﬂammatory
activity. This can easily be demonstrated by the aqueous dispersion of
lipid conjugates from DMSO solution resulting in nanoparticle forma-
tion and high potency. Similarly, the formation of DOPE-TLR7a parti-
cles in the form of MLV liposomes signiﬁcantly increased in vitro pro-
inﬂammatory potency over the unconjugated TLR7a. SAXS data pro-
vided insight into the physical form of the conjugate after DMSO dis-
solution and aqueous dispersion, identifying a lamellar structure with
repeat distance of 77 ± 25 Å, and with the modelled parameters listed
in Table 5 correspond with groups of lamella in repeats with 3 bilayers.
When liposomes containing DOPE-TLR7a conjugate were compared to
previously characterized DDA:TDB liposomes, the most dramatic in-
crease in potency was observed simply by the initial formulation into
liposomes, rather than by combining multiple immunostimulatory
agents. We demonstrated control over the DOPE-TLR7a content in-
tegrated in the liposomes and highlight the potential of liposomal for-
mulation of this TLR7 agonist to achieve highly potent PRR activation.
Formulations of particles containing TLR7a either as MLV or micelles
via dissolution into DMSO prior to aqueous dilution are both equally
potent inducers of IL-12p40. The most signiﬁcant change in pro-in-
ﬂammatory activity following lipid conjugation could be attributed to
the formation of sub-micron particles. Overall, this study highlights the
importance of physical form and formulation on activity of im-
munostimulatory compounds which trigger PRR.
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